Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Philogen Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Dario Neri

İcra Kurulu Başkanı

€150.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	28.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Dario Neri (61 yo)

28.8yrs

Görev süresi

€150,000

Tazminat

Prof. Dr. Dario Neri, PhD co-founded Philogen S.p.A in 1996 and serves as its CSO, President of The Scientific Advisory Board and Chief Executive Officer and Managing Director. Prof. Dr. Neri served as Sc...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Duccio Neri	Co-Founder & Executive Chairman	no data	€300.00k	Veri yok
Dario Neri	Co-Founder	no data	€150.00k	Veri yok
Giovanni Neri	Co-Founder	no data	€90.00k	Veri yok
Roberto Ferraresi	Independent Director	5.4yrs	€32.00k	Veri yok
Sergio Gianfranco Luigi Dompé	Director	no data	€30.00k	0.025% € 197.0k
Leopoldo Zambeletti	Director	no data	€30.00k	Veri yok
Nathalie Francesca Dompé	Director	no data	€30.00k	Veri yok
Guido Guidi	Member of Scientific Advisory Board & Director	5.4yrs	€32.00k	Veri yok
Marta Bavasso	Lead Independent Director	no data	€30.00k	Veri yok
Wolfgang Berdel	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Cornelia Winter	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Maria Calloni	Director	2.8yrs	€32.00k	Veri yok

5.4yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 78Q 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).

Philogen Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Director recently bought €179k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Director recently bought €377k worth of stock

Director recently bought €76k worth of stock

Recent updates

First half 2024 earnings released

Less than half of directors are independent

Director recently bought €179k worth of stock

Full year 2023 earnings released

Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma

Philogen S.p.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities

New major risk - Revenue and earnings growth

Philogen S.P.A. and Sun Pharmaceutical Industries Limited Announces Positive Results from the Phase III Pivotal Trial in Patients with Locally Advanced Fully Ressectable Melanoma

First half 2023 earnings released: EPS: €0.19 (vs €0.049 in 1H 2022)

Philogen S.p.A. (BIT:PHIL) commences an Equity Buyback Plan for 500,000 shares, representing 1.23% of its issued share capital, under the authorization approved on April 28, 2023.

Less than half of directors are independent

First half 2022 earnings released: EPS: €0 (vs €0.21 loss in 1H 2021)

Philogen S.p.A. Announces Enrolment of 214 Patients in the Nidlegy Phase III European Clinical Trial for the Treatment of Locally Advanced Melanoma

Less than half of directors are independent

Full year 2021 earnings released

Director recently bought €377k worth of stock

Director recently bought €76k worth of stock

Director recently bought €4.7m worth of stock

Director recently bought €4.4m worth of stock

Philogen S.p.A. Announces R&D Program Update

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş